ATRC vs PATH · rev $465.3M vs P/E 19, rev $1.61B
AtriCure Inc (ATRC) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
AtriCure Inc (ATRC) is a medical instruments & supplies company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported ATRC revenue for 2024-12-31 was $465.3M. Net income was -$44.7M. Revenue was up 16.5% from 2023-12-31 to 2024-12-31. ATRC currently screens at market cap $1.37B.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
ATRC currently screens at market cap $1.37B. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the ATRC and PATH stock pages for the full models.
Not investment advice.